EDN1 and Hypertension: This may be attributed to the multi-target antiangiogenic nature of anlotinib, which could elicit alterations in nitric oxide, endothelin-1, microvascular rarefaction, selective vasoconstrictions and renal injury, all of which have been cited as potential mechanisms leading to anlotinib-induced hypertension [28].